Xilio Therapeutics (XLO) Stock News, Feb-Jun 2025

Xilio Therapeutics, a clinical-stage biotech company focused on tumor-activated immuno-oncology therapies, has announced a proposed public offering of pre-funded warrants to purchase common stock. The offering includes Series A, B, and C warrants, with all securities being offered by Xilio. The company plans to use the proceeds to advance its product candidate development and for working capital and general corporate purposes. Leerink Partners is serving as the sole bookrunner for the offering. The offering will be made through a shelf registration statement on Form S-3 that was filed with the SEC on March 11, 2025, and declared effective on May 8, 2025. The final terms and completion of the offering are subject to market conditions.

Xilio Therapeutics (XLO) reported promising Phase 2 data for vilastobart combined with atezolizumab in treating metastatic microsatellite stable colorectal cancer (MSS CRC). The trial showed a 26% preliminary objective response rate in patients without liver metastases, with responses lasting up to 37 weeks. Of 44 treated patients (median age 55), 80% had received three or more prior cancer therapies. The drug combination demonstrated a favorable safety profile with only 7% of patients experiencing colitis. Seven partial responses were observed in patients without liver metastases, with six confirmed responses. The treatment showed substantial decreases in tumor biomarkers and improved clinical symptoms. Xilio is now enrolling patients at a higher dose level (150mg Q6W) and plans to report additional data in H1 2026. The company is seeking partnership opportunities to advance the vilastobart program.

Xilio Therapeutics (XLO) reported Q1 2025 financial results and pipeline updates. Key highlights include: promising Phase 2 data for vilastobart (anti-CTLA-4) combined with atezolizumab, showing 27% objective response rate in MSS CRC patients without liver metastases. The company is advancing multiple masked T cell engager programs, with first development candidates expected in H2 2025. Financially, Xilio ended Q1 with $89.1 million in cash, boosted by a $52 million upfront payment from AbbVie collaboration. Q1 revenue was $2.9M, with reduced R&D expenses at $8.3M (vs $10.4M in Q1 2024) and increased G&A expenses at $8.5M (vs $6.1M). Net loss improved to $13.3M from $17.2M year-over-year. Current cash runway extends into Q1 2026.

Xilio Therapeutics (XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to a new employee. The inducement grant includes options to purchase 5,000 shares of common stock at an exercise price of $0.755 per share, equal to the closing price on May 1, 2025. The options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (Nasdaq: XLO) has announced it will present updated Phase 2 clinical trial data for vilastobart (XTX101) at the 2025 ASCO Annual Meeting. The presentation will focus on the combination therapy of vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC).

The data presentation is scheduled for Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT during the Gastrointestinal Cancer - Colorectal and Anal poster session at the conference in Chicago, Illinois. The abstract ID is 3553 and will be displayed on Poster Board 222.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced new employee stock option grants. The company granted non-qualified stock options to three new employees to purchase a total of 22,900 shares of common stock, effective April 1, 2025.

The stock options were issued under Xilio's 2022 Inducement Stock Incentive Plan with an exercise price of $0.7244 per share, matching the closing price on March 31, 2025. The options have a ten-year term and follow a vesting schedule of 25% after the first year, with the remaining 75% vesting in 36 monthly installments, contingent on continued employment.

Xilio Therapeutics (XLO) reported key pipeline and financial updates for Q4 and full year 2024. The company highlighted promising Phase 2 data for vilastobart, showing a 27% objective response rate in MSS CRC patients without liver metastases, with only 5% reporting colitis.

The company announced a significant collaboration with AbbVie in Q1 2025, receiving $52.0 million in upfront payments, including a $10.0 million equity investment, with potential for up to $2.1 billion in milestone payments plus royalties.

Financial highlights include: Cash position of $55.3 million as of December 31, 2024; License revenue of $6.3 million for 2024; R&D expenses decreased to $41.2 million from $52.1 million in 2023; Net loss improved to $58.2 million from $76.4 million in 2023. The company expects current cash runway into Q1 2026.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.

The company's president and chief executive officer, René Russo, Pharm.D., will engage in a fireside chat on Monday, March 3, 2025, at 9:50 am EST.

Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's investor relations website at ir.xiliotx.com. The webcast recording will remain available on the website for 30 days after the presentation.

Xilio Therapeutics (Nasdaq: XLO) announced three preclinical programs for masked T cell engagers targeting PSMA, CLDN18.2, and STEAP1. The company also entered into a collaboration agreement with AbbVie, receiving $52.0 million in upfront payments ($42.0M cash and $10.0M equity investment).

The collaboration includes an exclusive option for AbbVie to develop masked cell engager molecules and a license for masked antibody-based immunotherapy, with potential additional payments up to $2.1 billion plus tiered royalties. Xilio's technology aims to improve T cell engager tolerability through tumor-selective activation.

Development timelines include: PSMA candidate nomination in Q3 2025 (IND in Q1 2027), CLDN18.2 candidate in Q4 2025 (IND in Q2 2027), and STEAP1 candidate in H1 2026 (IND in H2 2027). The company's cash runway has been extended into Q1 2026.